Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, hepatocellular carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, liposarcoma, liver disorder, mesonephric neoplasm, mixed neoplasm, myomatous neoplasm, neoplasm, rhabdoid tumor, rhabdomyosarcoma, sarcoma, undifferentiated embryonal sarcoma of the liver, urinary system disorder, yolk sac tumor	Active, not recruiting	Phase 1	2026-03-06		NCT05103631

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baylor College of Medicine	267
Center for Cell and Gene Therapy, Baylor College of Medicine	40
The Methodist Hospital Research Institute	124

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Houston Methodist Hospital	Houston	United States	260